Atlas Trials

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

Clinical trial NCT02520752 · COMPLETED

Trial details

NCT number
NCT02520752
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
cMET-dysregulated Advanced Solid Tumors
Start date
2015-12-10
Primary completion
2017-01-30
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.